Toronto, ON (September 29, 2008) – Nometics Inc., a clinical-stage pharmaceutical company that is developing oncology products, announces the formation of its US Clinical Advisory Board. The board Chair is Dr. Lawrence Einhorn, past president of the American Society of Clinical Oncology (ASCO) and Distinguished Professor and Lance Armstrong Foundation Chair in Oncology at Indiana University. Dr. David H. Johnson (Director, Division of Hematology/Oncology Vanderbilt-Ingram Cancer Centre) and Dr. David Sidransky (Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine) have also joined; both are also past presidents of ASCO. This Advisory Board will play an important role in directing the clinical development program for the company’s lead product, NOVadeTM.
“We are very pleased to have attracted these outstanding oncologists to our Clinical Advisory Board,” stated Roger Sharpe, President of Nometics Inc. “They bring great depth of experience and knowledge in all areas of clinical oncology & drug development to our company.”
About Nometics Inc.
Nometics Inc. is a private specialty pharmaceutical company focused on the development & commercialization of late stage oncology products. The company’s lead compound, NOVade™ is a low-dose formulation of transdermal nitroglycerin. NOVade™ has demonstrated pre-clinical and clinical success in treating a wide variety of cancers including non-small cell lung, breast, melanoma and prostate cancer (the latter was the subject of a phase I/II trial). NOVade™ has demonstrated the capacity to work both alone, or in combination with standard anti-neoplastic therapies.
Nometics Inc. is building on clinical results and a strong research base which has elucidated a unique mode of action in metastatic cancer cells. The Company expects to start advanced clinical trials in 2009. (www.nometicsinc.com)
